Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series

Labidi, Sana Intidhar; Bachelot, Thomas; Ray‐Coquard, Isabelle; Mosbah, Karim; Treilleux, Isabelle; Fayette, Jérôme; Favier, Bertrand; Galy, G.; Blay, Jean‐Yves; Guastalla, Jean‐Paul

doi:10.3816/cbc.2009.n.021

Cited by 60 publications

(37 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PASSPORT study of patients with non-small lung cell carcinoma (NSCLC) and nonprogressive brain metastases after RT demonstrated that bevacizumab in addition to chemotherapeutic agents or erlotinib did not induce grade 2 ICH and that bevacizumab can be safely used in patients with brain metastases (56). A small series of patients with progressive brain metastases who failed on RT or surgery plus RT and received treatment with bevacizumab with or without chemotherapeutic agents were reported for breast cancer (57,58), NSCLC (59) and colorectal cancer (60). The ORR of the studies was 33 -100%, and the PFS and OS of patients with breast cancer and brain metastases were 2.8 -9 and 7.8 months, respectively.…”

Section: Brain Metastasesmentioning

confidence: 99%

Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors

Narita¹

2013

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Glioblastoma is a highly vascular tumor that expresses vascular endothelial growth factor, a key regulator of angiogenesis and tumor blood vessel permeability. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor and the growth of gliomas. Bevacizumab monotherapy has proven effective for recurrent glioblastoma, and it extended progression-free survival and improved patient quality of life in various clinical trials. Some patients who receive bevacizumab experience improvements in neurological symptoms and steroid dose reductions. Bevacizumab induces a dramatic and rapid radiological response, but non-enhancing lesions are often detected on magnetic resonance imaging without enhancing lesions. Rebound phenomena such as rapid tumor regrowth are occasionally observed after the discontinuation of bevacizumab therapy. Therefore, Response Assessment in Neuro-Oncology criteria were recently devised to evaluate the efficacy and radiological response of bevacizumab treatment. Hypertension and proteinuria are characteristic adverse events associated with bevacizumab therapy. In addition, many fatal adverse events such as intracranial hemorrhage and venous thromboembolism are reported in patients treated with bevacizumab. However, these events are also associated with glioma itself, and careful attention needs to be paid to these events. Bevacizumab is used to treat various diseases including radiation necrosis and recurrent brain tumors such as brain metastases, schwannoma and meningioma, but additional clinical trials are necessary. The efficacy and current problems associated with bevacizumab in the treatment of glioblastoma and other brain tumors are reviewed.

show abstract

Section: Brain Metastasesmentioning

confidence: 99%

Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors

Narita¹

2013

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Significant anti-tumor activity was observed, with one complete response (CR) and three PRs in the CNS metastases. With a mean follow-up of 9 months, duration of response for the four patients was 11, 10, 8 and 6 months, respectively [23]. These preliminary results require further confirmation on a larger and more homogeneous series of patients.…”

Section: Editorialmentioning

confidence: 90%

The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

Addeo

Caraglia

2011

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

“…As noted above, several studies have demonstrated the efficacy and safety of bevaci- (6)(7)(8)(9)(10)(11), and other types of cancers (12)(13)(14), especially in recurrent glioblastoma patients. In patients with chemotherapy-and radiotherapy-refractory glioblastoma, bevacizumab showed effectiveness as a monotherapy or in combination with cytotoxic agents (15)(16)(17).…”

Section: Discussionmentioning

confidence: 99%

Bevacizumab for Critical Brain Metastases in a Patient with Pulmonary Pleomorphic Carcinoma

et al. 2014

View full text Add to dashboard Cite

Bevacizumab was initially contraindicated in patients with brain metastases, but several reports have shown the efficacy and safety of bevacizumab for brain metastases. We herein report the case of a patient with pulmonary pleomorphic carcinoma for which bevacizumab plus weekly paclitaxel following whole-brain radiotherapy (WBRT) was effectively and safely administered for critical and refractory brain metastases. Although the 50-year-old male patient received WBRT with anti-edema therapies for progressive brain metastases, his clinical symptoms deteriorated rapidly. After the completion of WBRT, we administered bevacizumab plus weekly paclitaxel, and his neurological symptoms improved dramatically. Brain magnetic resonance imaging demonstrated a marked response by the brain metastases and improved brain edema. This case suggested both synergism between WBRT and bevacizumab, and an anti-edema effect of bevacizumab. Bevacizumab may be therefore a potent therapeutic option for patients with refractory brain metastases.

show abstract

Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series

Cited by 60 publications

References 13 publications

Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors

Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors

The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

Bevacizumab for Critical Brain Metastases in a Patient with Pulmonary Pleomorphic Carcinoma

Contact Info

Product

Resources

About